Phar­ma reps need to bone up on sci­en­tif­ic da­ta and re­al-world ev­i­dence for on­col­o­gy dis­cus­sions: study

On­col­o­gists would like a word with phar­ma com­pa­nies. More than a word, ac­tu­al­ly – they’d like en­tire in-depth con­ver­sa­tions with drug ex­perts and more re­al-world da­ta, please.

That’s ac­cord­ing to Ac­cen­ture’s new study look­ing at on­col­o­gists’ needs through a phar­ma lens. The study comes as FDA ap­proved 16 nov­el can­cer drugs in 2021 – in­clud­ing the first KRAS in­hibitor – along with more than 40 new in­di­ca­tions in on­col­o­gy and hema­tol­ogy. Mean­while, on­col­o­gy tri­als are at record lev­els, up 60% from just five years ago, Ac­cen­ture not­ed in its re­port.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER